인간 마이크로바이옴 치료제 시장(2026-2030년)

The global human microbiome therapeutics market is forecasted to grow by USD 943069.2 thousand during 2025-2030, accelerating at a CAGR of 20.5% during the forecast period. The report on the global human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of chronic gastrointestinal and metabolic diseases, technological advancements in metagenomic sequencing and ai, accelerated regulatory pathways and increasing capital inflows.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global human microbiome therapeutics market is segmented as below:

By Product

• Probiotics
• Prebiotics
• Medical foods
• Prescription drugs

By Application

• Gastrointestinal disorders
• Infectious diseases
• Others

By Route Of Administration

• Oral
• Rectal
• Injectable
• Topical

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the transition toward rationally designed and engineered synthetic consortia as one of the prime reasons driving the global human microbiome therapeutics market growth during the next few years. Also, integration of microbiome-based therapies as immuno-oncology adjuvants and expansion of clinical focus beyond gastrointestinal targets to gut-brain axis will lead to sizable demand in the market.

The report on the global human microbiome therapeutics market covers the following areas:

• Global human microbiome therapeutics market sizing
• Global human microbiome therapeutics market forecast
• Global human microbiome therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global human microbiome therapeutics market vendors that include BioGaia Group, BiomeBank, Danone SA, Ferring BV, International Flavors Inc., Johnson and Johnson, Lallemand Inc., Morinaga Milk Industry, Nestle Health Science S.A., Novonesis Group, OptiBiotix Health Plc, Pendulum Therapeutics Inc., Probi AB, ResBiotic, Seed Health, Takeda Pharmaceutical Ltd., Vedanta Biosciences Inc., Yakult Honsha Co. Ltd.. Also, the global human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Product
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Human Microbiome Therapeutics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Human Microbiome Therapeutics Market 2020 - 2024 ($ thousand)
• 5.2 Product segment analysis 2020 - 2024
  • Historic Market Size - Product Segment 2020 - 2024 ($ thousand)
• 5.3 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ thousand)
• 5.4 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ thousand)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ thousand)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ thousand)

6 Qualitative Analysis

• 6.1 Impact of AI on global human microbiome therapeutics market
• 6.2 Impact of geopolitical conflicts on global human microbiome therapeutics market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Product

• 8.1 Market segments
• 8.2 Comparison by Product
• 8.3 Probiotics - Market size and forecast 2025-2030
• 8.4 Prebiotics - Market size and forecast 2025-2030
• 8.5 Medical foods - Market size and forecast 2025-2030
• 8.6 Prescription drugs - Market size and forecast 2025-2030
• 8.7 Market opportunity by Product
  • Market opportunity by Product ($ thousand)

9 Market Segmentation by Application

• 9.1 Market segments
• 9.2 Comparison by Application
• 9.3 Gastrointestinal disorders - Market size and forecast 2025-2030
• 9.4 Infectious diseases - Market size and forecast 2025-2030
• 9.5 Others - Market size and forecast 2025-2030
• 9.6 Market opportunity by Application
  • Market opportunity by Application ($ thousand)

10 Market Segmentation by Route of Administration

• 10.1 Market segments
• 10.2 Comparison by Route of Administration
• 10.3 Oral - Market size and forecast 2025-2030
• 10.4 Rectal - Market size and forecast 2025-2030
• 10.5 Injectable - Market size and forecast 2025-2030
• 10.6 Topical - Market size and forecast 2025-2030
• 10.7 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ thousand)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 France - Market size and forecast 2025-2030
  • 12.4.3 UK - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 Japan - Market size and forecast 2025-2030
  • 12.5.2 China - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ thousand)
  • Data Tables on Market opportunity by geography ($ thousand)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Rising incidence of chronic gastrointestinal and metabolic diseases
  • Technological advancements in metagenomic sequencing and AI
  • Accelerated regulatory pathways and increasing capital inflows
• 13.2 Market challenges
  • High vulnerability to clinical trial attrition and unpredictable biological efficacy
  • Strict manufacturing standardization and technical scaling barriers
  • Severe regulatory fragmentation and lack of global standardization
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Transition toward rationally designed and engineered synthetic consortia
  • Integration of microbiome-based therapies as immuno-oncology adjuvants
  • Expansion of clinical focus beyond gastrointestinal targets to gut-brain axis

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 BioGaia Group
  • BioGaia Group - Overview
  • BioGaia Group - Business segments
  • BioGaia Group - Key offerings
  • BioGaia Group - Segment focus
  • SWOT
• 15.5 BiomeBank
  • BiomeBank - Overview
  • BiomeBank - Product / Service
  • BiomeBank - Key offerings
  • SWOT
• 15.6 Danone SA
  • Danone SA - Overview
  • Danone SA - Business segments
  • Danone SA - Key offerings
  • Danone SA - Segment focus
  • SWOT
• 15.7 Ferring BV
  • Ferring BV - Overview
  • Ferring BV - Product / Service
  • Ferring BV - Key offerings
  • SWOT
• 15.8 International Flavors Inc.
  • International Flavors Inc. - Overview
  • International Flavors Inc. - Business segments
  • International Flavors Inc. - Key news
  • International Flavors Inc. - Key offerings
  • International Flavors Inc. - Segment focus
  • SWOT
• 15.9 Johnson and Johnson
  • Johnson and Johnson - Overview
  • Johnson and Johnson - Business segments
  • Johnson and Johnson - Key news
  • Johnson and Johnson - Key offerings
  • Johnson and Johnson - Segment focus
  • SWOT
• 15.10 Lallemand Inc.
  • Lallemand Inc. - Overview
  • Lallemand Inc. - Product / Service
  • Lallemand Inc. - Key offerings
  • SWOT
• 15.11 Morinaga Milk Industry
  • Morinaga Milk Industry - Overview
  • Morinaga Milk Industry - Product / Service
  • Morinaga Milk Industry - Key offerings
  • SWOT
• 15.12 Nestle Health Science S.A.
  • Nestle Health Science S.A. - Overview
  • Nestle Health Science S.A. - Product / Service
  • Nestle Health Science S.A. - Key offerings
  • SWOT
• 15.13 Novonesis Group
  • Novonesis Group - Overview
  • Novonesis Group - Business segments
  • Novonesis Group - Key offerings
  • Novonesis Group - Segment focus
  • SWOT
• 15.14 Pendulum Therapeutics Inc.
  • Pendulum Therapeutics Inc. - Overview
  • Pendulum Therapeutics Inc. - Product / Service
  • Pendulum Therapeutics Inc. - Key offerings
  • SWOT
• 15.15 ResBiotic
  • ResBiotic - Overview
  • ResBiotic - Product / Service
  • ResBiotic - Key offerings
  • SWOT
• 15.16 Seed Health
  • Seed Health - Overview
  • Seed Health - Product / Service
  • Seed Health - Key offerings
  • SWOT
• 15.17 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.18 Yakult Honsha Co. Ltd.
  • Yakult Honsha Co. Ltd. - Overview
  • Yakult Honsha Co. Ltd. - Business segments
  • Yakult Honsha Co. Ltd. - Key offerings
  • Yakult Honsha Co. Ltd. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations